RxDoctor Payments Data

Saba Shabnam, MD

Family Medicine · Grapevine, TXNPI 1225091655

Payments from drug & device makers

$870in general payments, 2019–2025

Across 39 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$248
  • GSK$111
  • Amgen$88
  • Novo Nordisk$81
  • Shield Therapeutics Inc$79
  • Lilly USA, LLC$50
  • plus $213 from 9 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,076
Medicare patients
68
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$107,324
FarxigaDapagliflozin Propanediol58$48,550
OzempicSemaglutide41$39,075
JardianceEmpagliflozin28$28,990
Synjardy XrEmpagliflozin/Metformin Hcl40$28,684
VascepaIcosapent Ethyl39$21,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,174
LinzessLinaclotide11$13,837
Xigduo XrDapaglifloz Propaned/Metformin24$12,521
Ezetimibe85$3,262
Rosuvastatin Calcium284$3,005
Icosapent Ethyl11$1,846
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide15$1,763
FenofibrateFenofibrate Nanocrystallized35$1,222
ProgesteroneProgesterone, Micronized40$1,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$50$107,32496 claims
Boehringer IngelheimJardiance, Synjardy Xr$41$57,67468 claims
AstraZenecaFarxiga$248$48,55058 claims
Novo NordiskOzempic$81$39,07541 claims
GSKTrelegy Ellipta$111$15,17417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grapevine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →